FDA calendar · November 2023 · built from SEC filings

PDUFA dates November 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

2 PDUFA dates fell in November 2023: ABEO (Nov 2023), reproxalap (November 23). The FDA calendar also recorded 30 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in November 2023

2 PDUFA target action dates in November 2023, soonest first, each linked to the SEC filing or FDA page that disclosed it. Data as of .
PDUFA dateCompanyTickerDrugIndicationSource
Nov 2023ABEONA THERAPEUTICS INC.ABEONot namedSEC Form 10-K, filed 2025-03-20
November 23, 2023Aldeyra Therapeutics, Inc.ALDXreproxalapSEC Form 10-Q, filed 2025-05-14

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

November 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Nov 2023Month disclosed—ALDXComplete Response Letter—CRL issuedSEC 8-K Exhibit 99.1
Nov 2023Month disclosedOGSIVEO® (nirogacestat)IMNMFDA approval—ApprovedSEC Form 10-Q
Nov 2023Month disclosedVOQUEZNA® (vonoprazan)PHATNDA/BLA submission—CompletedSEC Form 10-K
November 1, 2023VOQUEZNA® (vonoprazan)PHATFDA approvalerosive gastroesophageal reflux disease, or Erosive GERDApprovedSEC Form 10-Q
November 1, 2023Sarclisa (isatuximab-irfc)SNYLabel expansion—ApprovedopenFDA Drugs@FDA
November 6, 2023LYNPARZA® (olaparib)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
November 7, 2023KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
November 8, 2023Zepbound (tirzepatide)LLYFDA approval—ApprovedopenFDA Drugs@FDA
November 8, 2023FRUZAQLA® (fruquintinib)TAKFDA approvalTo treat refractory, metastatic colorectal cancerApprovedSEC 8-K Exhibit 99.1
November 15, 2023AUGTYRO (repotrectinib)BMYFDA approvalTo treat ROS1-positive non-small cell lung cancerApprovedFDA Novel Drug Approvals
November 15, 2023DefenCathCRMDFDA approvalkidney failure receiving chronic hemodialysisApprovedsec_424b
November 15, 2023Defencath (heparin sodium; taurolidine)CRMDFDA approval—ApprovedFDA Novel Drug Approvals
November 16, 2023Truqap (capivasertib)AZNFDA approvalTo treat breast cancer that meets certain disease criteriaApprovedFDA Novel Drug Approvals
November 21, 2023TAXOL® (paclitaxel)TEVALabel expansion—ApprovedopenFDA Drugs@FDA
November 27, 2023reproxalapALDXComplete Response Lettersigns and symptoms of dry eye disease in December 2022CRL issuedSEC Form 10-Q
November 27, 2023reproxalapALDXNDA/BLA submissionsigns and symptoms of dry eye disease in December 2022CompletedSEC Form 10-Q
November 29, 2023Alvaiz (eltrombopag choline)TEVAFDA approval—ApprovedopenFDA Drugs@FDA

November 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Nov 2023Month disclosedSimponi®ALVOTopline readout—PositiveSEC 8-K Exhibit 99.1
Nov 2023Month disclosedfluoroquinoloneINVATopline readout—PositiveSEC Form 10-K
Nov 2023Month disclosedPSA-201MLTXTopline readoutactive PsAMet primary endpointSEC Form 10-Q
November 30, 2023HLP003HELPTopline readout—Met primary endpointSEC 8-K Exhibit 99.1
November 30, 2023CYB003HELPTopline readout—Met primary endpointSEC 8-K Exhibit 99.1

November 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Nov 2023Month disclosedGOHIBIC (vilobelimab)IFRXTrial start—CompletedSEC Form 10-K
Nov 2023Month disclosedremlifanserin (ACP-204)ACADTrial starthallucinations and delusions associated with ADPCompletedSEC Form 10-Q
Nov 2023Month disclosedpipe-307 dose a (PIPE-307)CTNMTrial startRRMS, referred toCompletedSEC Form 10-K
Nov 2023Month disclosedPSA-201MLTXTrial startactive PsACompletedSEC Form 10-Q
November 6, 2023lanifibranor (IVA337)IVATrial startT2D and NAFLD sponsoredCompletedSEC Form 10-K
Nov 2023Month disclosedAMT-19QURETrial start—CompletedSEC Form 10-Q
Nov 2023Month disclosedAMT-191QURETrial start—CompletedSEC Form 10-K
Nov 2023Month disclosedAPHEXDA® (motixafortide)BLRXTrial start—CompletedSEC 8-K Exhibit 99.1

Questions

What PDUFA dates are in November 2023?

2 PDUFA dates fell in November 2023: ABEO (Nov 2023), reproxalap (November 23). The FDA calendar also recorded 30 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.